
Opinion|Videos|April 4, 2025
Incorporating Bispecific Antibodies Earlier in Treatment and Improving Access in Underserved Communities
Experts discuss how bispecifics might be incorporated earlier in the lines of treatment for certain cancers, the steps that can be taken to improve access to bispecific therapies in underserved or rural community settings, and how partnerships among academic centers, manufacturers, and community practices can help accelerate the adoption of bispecific antibodies.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How might bispecifics be incorporated earlier in the lines of treatment for certain cancers?
- What steps can be taken to improve access to bispecific therapies in underserved or rural community settings?
- How can partnerships between academic centers, manufacturers, and community practices help accelerate the adoption of bispecific antibodies?
Advertisement
Related to this article

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.

San Francisco experts say earlier IgA nephropathy and FSGS detection depends on primary care education and care coordinators.

The FDA has approved secukinumab for PMR after the REPLENISH trial showed doubled sustained remission and lower steroid use vs a steroid taper alone.

Earlier MASH fibrosis detection is more urgent now that treatments exist, and automating FIB-4 in EHRs could help primary care, says Rohit Loomba, MD.

In this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ESMO 2026 Congress.

Neladalkib earned accelerated approval for previously treated ALK-positive NSCLC, with ORRs of 49% and 32%.

FDA approved adrabetadex for infantile-onset Niemann-Pick disease type C after survival data showed 84% vs 42% 5-year survival with treatment.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First siRNA Therapy for AChR-Positive Myasthenia Gravis
2
Complicated UTI Care Strained by Unclear Goals, Access Gaps
3
Obesity Care Ownership Shifts to Specialties That Win Coverage
4
Emerging Threats to Cell and Gene Therapy Access
5


